Esophageal Cancer - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 429
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EF536FD5BCFEN
Leaflet:

Download PDF Leaflet

Esophageal Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Esophageal Cancer - Pipeline Review, H2 2016’, provides an overview of the Esophageal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Esophageal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
  • The report reviews pipeline therapeutics for Esophageal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Esophageal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Esophageal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Esophageal Cancer
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Esophageal Cancer Overview
Therapeutics Development
Pipeline Products for Esophageal Cancer - Overview
Pipeline Products for Esophageal Cancer - Comparative Analysis
Esophageal Cancer - Therapeutics under Development by Companies
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes
Esophageal Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Esophageal Cancer - Products under Development by Companies
Esophageal Cancer - Products under Investigation by Universities/Institutes
Esophageal Cancer - Companies Involved in Therapeutics Development
Adaptimmune Therapeutics Plc
Advaxis, Inc.
Advenchen Laboratories, LLC
Almac Discovery Limited
Amgen Inc.
ArQule, Inc.
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
ATLAB Pharma SAS
Bayer AG
Betta Pharmaceuticals Co. Ltd.
Boehringer Ingelheim GmbH
Celgene Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Cerulean Pharma, Inc.
Cyclacel Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Genmab A/S
GlaxoSmithKline Plc
Glycotope GmbH
Hutchison MediPharma Limited
Ignyta, Inc.
ImmunoFrontier, Inc.
Immunomedics, Inc.
Johnson & Johnson
Komipharm International Co., Ltd.
MacroGenics, Inc.
MaxiVAX SA
Mebiopharm Co., Ltd.
MedImmune, LLC
Merck & Co., Inc.
Mirna Therapeutics, Inc.
Novartis AG
Omeros Corporation
Omnitura Therapeutics Inc.
Oncolys BioPharma Inc
OncoMed Pharmaceuticals, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Proteo, Inc.
Puma Biotechnology, Inc.
Rhizen Pharmaceuticals S.A.
Shionogi & Co., Ltd.
Spectrum Pharmaceuticals, Inc.
Symphogen A/S
Taiho Pharmaceutical Co., Ltd.
Taiwan Liposome Company, Ltd.
Takara Bio Inc.
Transgene Biotek Limited
VioQuest Pharmaceuticals, Inc.
XuanZhu Pharma Co., Ltd.
Esophageal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(tipiracil hydrochloride + trifluridine) - Drug Profile
1-BB1 - DRUG PROFILE
ADXS-HER2 - Drug Profile
afatinib dimaleate - Drug Profile
AL-3818 - Drug Profile
ALM-301 - Drug Profile
alpelisib - Drug Profile
AMG-337 - Drug Profile
apatinib - Drug Profile
atezolizumab - Drug Profile
ATL-101 - Drug Profile
binimetinib - Drug Profile
brontictuzumab - Drug Profile
CDX-1401 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile
Cellular Immunotherapy to Target NY-ESO-1 for Oncology - Drug Profile
cetuximab biobetter - Drug Profile
CGX-1321 - Drug Profile
CRLX-101 - Drug Profile
CYC-140 - Drug Profile
DKN-01 - Drug Profile
donafenib - Drug Profile
durvalumab - Drug Profile
elgemtumab - Drug Profile
erdafitinib - Drug Profile
futuximab - Drug Profile
ganetespib - Drug Profile
gedatolisib - Drug Profile
GSK-2256098 - Drug Profile
GSK-3377794 - Drug Profile
HMPL-309 - Drug Profile
I131-CLR1404 - Drug Profile
icotinib hydrochloride - Drug Profile
IMF-001 - Drug Profile
JS-001 - Drug Profile
KML-001 - Drug Profile
margetuximab - Drug Profile
MBP-426 - Drug Profile
miR-215 - Drug Profile
MMD-37K - Drug Profile
Monoclonal Antibodies to Inhibit PD-L2 for Esophageal Cancer - Drug Profile
MVXONCO-1 - Drug Profile
neratinib - Drug Profile
nimotuzumab - Drug Profile
nintedanib - Drug Profile
nivolumab - Drug Profile
OBP-301 - Drug Profile
OMN-54 - Drug Profile
paclitaxel albumin bound - Drug Profile
panitumumab - Drug Profile
pasireotide ER - Drug Profile
PCA-062 - Drug Profile
pembrolizumab - Drug Profile
pralatrexate - Drug Profile
RXDX-106 - Drug Profile
S-222611 - Drug Profile
S-588410 - Drug Profile
sacituzumab - Drug Profile
SDS-eCAR - Drug Profile
sirotinib - Drug Profile
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile
SMYD-2BAY02 - Drug Profile
TBI-1201 - Drug Profile
TBL-0805E - Drug Profile
TGR-1202 - Drug Profile
tiprelestat - Drug Profile
tisotumab vedotin - Drug Profile
tivantinib - Drug Profile
TLC-388 - Drug Profile
triciribine phosphate - Drug Profile
Vaccine for Esophageal Cancer and Colorectal Cancer - Drug Profile
varlitinib - Drug Profile
YQ-23 - Drug Profile
Esophageal Cancer - Dormant Projects
Esophageal Cancer - Discontinued Products
Esophageal Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 424

LIST OF TABLES

Number of Products under Development for Esophageal Cancer, H2 2016
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Esophageal Cancer - Pipeline by Advaxis, Inc., H2 2016
Esophageal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
Esophageal Cancer - Pipeline by Almac Discovery Limited, H2 2016
Esophageal Cancer - Pipeline by Amgen Inc., H2 2016
Esophageal Cancer - Pipeline by ArQule, Inc., H2 2016
Esophageal Cancer - Pipeline by Array BioPharma Inc., H2 2016
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2016
Esophageal Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
Esophageal Cancer - Pipeline by Bayer AG, H2 2016
Esophageal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Esophageal Cancer - Pipeline by Celgene Corporation, H2 2016
Esophageal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2016
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2016
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2016
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Esophageal Cancer - Pipeline by Genmab A/S, H2 2016
Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2016
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H2 2016
Esophageal Cancer - Pipeline by Ignyta, Inc., H2 2016
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H2 2016
Esophageal Cancer - Pipeline by Immunomedics, Inc., H2 2016
Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2016
Esophageal Cancer - Pipeline by Komipharm International Co., Ltd., H2 2016
Esophageal Cancer - Pipeline by MacroGenics, Inc., H2 2016
Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2016
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2016
Esophageal Cancer - Pipeline by MedImmune, LLC, H2 2016
Esophageal Cancer - Pipeline by Merck & Co., Inc., H2 2016
Esophageal Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2016
Esophageal Cancer - Pipeline by Novartis AG, H2 2016
Esophageal Cancer - Pipeline by Omeros Corporation, H2 2016
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2016
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2016
Esophageal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2016
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Esophageal Cancer - Pipeline by Pfizer Inc., H2 2016
Esophageal Cancer - Pipeline by Proteo, Inc., H2 2016
Esophageal Cancer - Pipeline by Puma Biotechnology, Inc., H2 2016
Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Esophageal Cancer - Pipeline by Shionogi & Co., Ltd., H2 2016
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
Esophageal Cancer - Pipeline by Symphogen A/S, H2 2016
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Esophageal Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
Esophageal Cancer - Pipeline by Takara Bio Inc., H2 2016
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H2 2016
Esophageal Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016
Esophageal Cancer - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Esophageal Cancer - Dormant Projects, H2 2016
Esophageal Cancer - Dormant Projects (Contd..1), H2 2016
Esophageal Cancer - Dormant Projects (Contd..2), H2 2016
Esophageal Cancer - Dormant Projects (Contd..3), H2 2016
Esophageal Cancer - Dormant Projects (Contd..4), H2 2016
Esophageal Cancer - Discontinued Products, H2 2016 414

LIST OF FIGURES

Number of Products under Development for Esophageal Cancer, H2 2016
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Esophageal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 448 pages
Endometrial Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 412 pages
Kidney Cancer - Pipeline Review, H1 2015 US$ 1,600.00 Jun, 2015 · 847 pages
Peritoneal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 676 pages
Rectal Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 107 pages

Ask Your Question

Esophageal Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: